AlpVision: AI-Powered Counterfeit Detection for Pharmaceutical Packaging

Overview: How AlpVision’s AI-Driven Counterfeit Detection Platform Transforms Drug Safety

AlpVision is an AI-powered counterfeit-detection platform for the drug-safety category that helps verify the authenticity of pharmaceutical products and packaging. It addresses the risk of falsified, diverted, or tampered medicines by making product authentication faster and more practical across complex supply chains.

The platform uses invisible digital markings, product fingerprinting, and image-based authentication to compare scanned items against reference data and determine whether they are genuine. In pharmaceutical operations, this can support quicker screening at receiving, packaging, and distribution stages, reducing dependence on manual checks and helping teams make faster authenticity decisions.

For healthcare and life sciences organisations, AlpVision’s approach can improve visibility into suspicious products while lowering the operational burden of routine verification. Its focus on smartphone-based inspection and no-change deployment also makes it easier to integrate into existing packaging and quality workflows, which can shorten review cycles and strengthen counterfeit prevention without adding significant process friction.

Last checked on 2026-08-01: AlpVision remains active, continues to focus on pharmaceutical anti-counterfeiting, and still centres its offering on Cryptoglyph and Fingerprint authentication

What is AlpVision?

AlpVision is an anti-counterfeiting and product-authentication platform used in drug safety workflows to verify pharmaceutical packaging and moulded parts. It is aimed at pharmaceutical companies and supply chain stakeholders who need to detect counterfeit or diverted medicines across packaging, labelling, and distribution processes.

The platform differentiates itself through covert authentication methods such as Cryptoglyph and Fingerprint, which rely on invisible markings and microscopic surface features rather than visible security elements. Public materials describe smartphone- and scanner-based verification, but I did not find a separate regulatory clearance or clinical validation statement on the live site reviewed.

Why Do Leading Healthcare Teams Trust AlpVision?

• AlpVision has a documented collaboration with Nolato Medical on protecting primary plastic pharmaceutical packaging against counterfeiting.

• AlpVision’s Cryptoglyph technology was integrated into the PharmaLedger platform, indicating participation in a broader European pharma digitalisation initiative.

• The company signed a strategic licensing agreement with Digimarc in 2010 to strengthen anti-counterfeiting applications and expand market access.

• AlpVision reported a distribution agreement with ISID for Cryptoglyph in Japan, which suggests established channel partnerships beyond Europe.

• The company says its technology protects over 30 billion products annually, which is a scale signal relevant to buyer confidence.

• AlpVision states that its turnkey pharma solutions meet FDA 21 CFR Part 11 ERES requirements and align with GAMP 5 CSV guidelines.

• AlpVision says Cryptoglyph is FDA 21 CFR Part 11 compliant, and its pharma quality claims are a recurring part of the public footprint.

• AlpVision’s Fingerprint technology was described as LBMA-accredited in 2023, showing external recognition of its authentication approach.

• AlpVision launched a COVID-19 medicine protection initiative in 2020, indicating direct pharma-sector responsiveness during a public health emergency.